ArticleBMC infectious diseases2026
Prevalence and factors associated with hematological adverse events in RR-TB patients on linezolid-based regimens in Uganda: a multicenter retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLinezolid (LZD) is a cornerstone of rifampicin-resistant tuberculosis (RR-TB) treatment, yet its hematological adverse events (AEs), particularly anemia, leukopenia, and thrombocytopenia, remain understudied in resource-limited settings like Uganda. With a high RR-TB burden and comorbidities such as HIV and malnutrition, understanding the prevalence and risk factors of these hematological AEs is critical to improving treatment adherence and outcomes.
aimThis study aimed to determine the prevalence of hematological AEs and identify factors associated with hematological AEs among RR-TB patients receiving LZD-based regimens in Uganda. METHODOLOGY: A multicenter retrospective cohort study was conducted using medical records of RR-TB patients treated with LZD at four Ugandan hospitals (Mbale RRH, Iganga General Hospital, Moroto RRH, and St. Kizito Matany Hospital) from 2020 to 2024. Hematological AEs were defined as anemia (Hb < 12 g/dL in women or < 13 g/dL in men), thrombocytopenia (platelets < 150 × 10³/µL), and leukopenia (WBC < 3.7 × 10⁹/L). Sociodemographic, clinical, and treatment-related data were extracted. A modified Poisson regression model with robust standard errors was used to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (CI).
resultsAmong 412 patients, 62.9% (259/412) had at least one hematological AE at baseline or during follow-up, and 36.4% (150/412) had hematological AEs first detected after LZD initiation. Among patients with available baseline CBC, 40.0% (98/245) developed incident hematological AEs. First detected anemia, thrombocytopenia, and leukopenia occurred in 21.4% (88/412), 14.8% (61/412), and 13.8% (57/412) of patients, respectively. Rural residence (aPR 1.60, 95% CI 1.11-2.33) and divorced or widowed marital status (aPR 4.10, 95% CI 1.58-10.77) were independently associated with hematological AEs. Patients with hematological AEs had lower treatment success (83.0% vs. 93.5%) and higher loss to follow-up (15.1% vs. 5.9%) than those without AEs.
conclusionHematological AEs were frequent among RR-TB patients receiving LZD in Uganda and were associated with reduced treatment success and increased loss to follow-up, while mortality remained low. Rural residence and divorced or widowed marital status were independently associated with these events, highlighting the need for targeted monitoring in higher-risk groups. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.